Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2006-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.106.106013PMID 16763093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  2006cited by this paper
• CHARACTERIZATION OF RAT SMALL INTESTINAL AND COLON PRECISION-CUT SLICES AS AN IN VITRO SYSTEM FOR DRUG METABOLISM AND INDUCTION STUDIES

  2005cited by this paper
• Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

  2005cited by this paper
• Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans

  2005cited by this paper
• In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam

  2004cited by this paper
• Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

  2004cited by this paper
• CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam

  2004cited by this paper
• 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.

  2004cited by this paper
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• Cytochrome P450 3A expression and activity in the human small intestine

  2004cited by this paper
• UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• Differential expression and function of CYP2C isoforms in human intestine and liver.

  2003cited by this paper
• Clinical Pharmacokinetics of Atorvastatin

  2003cited by this paper
• Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

  2003cited by this paper
• Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

  2003cited by this paper
• Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

  2002cited by this paper
• Shed human enterocytes as a tool for the study of expression and function of intestinal drug‐metabolizing enzymes and transporters

  2002cited by this paper
• Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.

  2002cited by this paper
• Metabolic characterization of the major human small intestinal cytochrome p450s.

  2001cited by this paper
• CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.

  2001cited by this paper
• In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

  2000cited by this paper
• In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

  2000cited by this paper
• Comparison of CYP2D6 Content and Metoprolol Oxidation Between Microsomes Isolated from Human Livers and Small Intestines

  1999cited by this paper
• Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.

  1999cited by this paper
• Is the role of the small intestine in first-pass metabolism overemphasized?

  1999cited by this paper
• In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.

  1999cited by this paper
• Molecular and physical mechanisms of first-pass extraction.

  1999cited by this paper
• Characterization of human small intestinal cytochromes P-450.

  1999cited by this paper
• Effect of fluvoxamine on the pharmacokinetics of quinidine

  1999cited by this paper
• The barrier function of CYP3A4 and P-glycoprotein in the small bowel.

  1997cited by this paper
• Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

  1997cited by this paper
• Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.

  1997cited by this paper
• Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

  1997cited by this paper
• Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

  1996influential reference
• Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.

  1994cited by this paper
• CYP3A gene expression in human gut epithelium.

  1994cited by this paper

• Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges.

  2025cites this paper
• Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from kcat measurements in matched liver and intestinal samples

  2025cites this paper
• Leveraging Buprenorphine and Halofantrine as Tool Molecules to Develop a Novel Semi-Physiologically based Pharmacokinetic Model Accounting for Gastro-Intestinal Lymphatic Absorption and Enabling Cross-Species Translation

  2025cites this paper
• Characterization of small molecule drug clearance mechanisms using in vitro and in vivo approaches in drug discovery and development

  2025cites this paper
• Coumarin derivatives as anticancer agents targeting PI3K-AKT-mTOR pathway: a comprehensive literature review

  2025cites this paper
• Age-dependent pharmacokinetics of nifedipine in spontaneous hypertensive rats are associated with changes in gut microbiota and hepatic CYP3A1 expression.

  2025cites this paper
• Quantitatively Predicting Effects of Exercise on Pharmacokinetics of Drugs Using a Physiologically Based Pharmacokinetic Model

  2024cites this paper
• PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?

  2024cites this paper
• PBTK model-based analysis of CYP3A4 induction and the toxicokinetics of the pyrrolizidine alkaloid retrorsine in man

  2024cites this paper
• Ex vivo Gut-Hepato-Biliary organ perfusion model to characterize oral absorption, gut-wall metabolism, pre-systemic hepatic metabolism and biliary excretion; application to midazolam.

  2024cites this paper
• Experimental and computational models to investigate intestinal drug permeability and metabolism

  2023cites this paper
• PBTK modeling of the pyrrolizidine alkaloid retrorsine to predict liver toxicity in mouse and rat

  2023cites this paper
• Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase

  2022cites this paper
• The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health

  2022cites this paper
• Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants

  2022cites this paper
• R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini

  2022cites this paper
• Characterizing and Quantifying Extrahepatic Metabolism of (−)-Δ9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, (±)-11-Hydroxy-Δ9-THC (11-OH-THC)

  2022influential citation
• hiPSC disease modeling with 3D organoids

  2022cites this paper
• Variability in Human In Vitro Enzyme Kinetics.

  2021cites this paper
• Evaluation of Cinnamon (Cinnamomum Verum) Effects on Liver CYP450 2D1 Activity and Hepatic Clearance in Diabetic Rats

  2021cites this paper
• Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

  2021cites this paper
• Determination of CYP450 Expression Levels in the Human Small Intestine by Mass Spectrometry-Based Targeted Proteomics

  2021cites this paper
• Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes

  2020cites this paper
• Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin

  2020cites this paper
• CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.

  2020cites this paper
• Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin

  2020cites this paper
• Can combination therapy with insulin and metformin improve metabolic function of the liver, in type I diabetic patients? An animal model study on CYP2D1 activity

  2020cites this paper
• Prolonged‐Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers

  2019cites this paper
• CYP450 activities before and after Roux-en-Y gastric bypass: correlation with their intestinal and liver content.

  2019cites this paper
• Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

  2019cites this paper
• Human Efflux Transporters in Drug Disposition : in vitro Transport of Glucuronide Metabolites

  2019cites this paper
• Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model

  2019cites this paper
• Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids

  2019cites this paper
• Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective

  2019cites this paper
• A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum

  2019cites this paper
• Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine

  2019influential citation
• Development of organoid-based drug metabolism model.

  2019cites this paper
• A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity

  2019cites this paper
• Protein Abundance of Clinically Relevant Drug‐Metabolizing Enzymes in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens

  2018cites this paper
• Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes.

  2018cites this paper
• LC–MS/MS method for the simultaneous quantification of intestinal CYP and UGT activity

  2018cites this paper
• Differential regulation of intestinal and hepatic CYP3A by 1α,25‐dihydroxyvitamin D3: Effects on in vivo oral absorption and disposition of buspirone in rats

  2018cites this paper
• Expression of clinically relevant drug‐metabolizing enzymes along the human intestine and their correlation to drug transporters and nuclear receptors: An intra‐subject analysis

  2018cites this paper
• Pharmacokinetic Interactions and Pharmacogenetics of Clopidogrel, Prasugrel and Ticagrelor

  2018cites this paper
• A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways

  2018cites this paper
• Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers

  2017cites this paper
• ADME Optimization in Drug Discovery

  2017cites this paper
• Quantifying gut wall metabolism: methodology matters

  2017cites this paper
• Bio-relevant characterisation of lipidic formulations and prediction of in vivo exposure

  2017cites this paper
• Functional expression and comparative characterization of four feline P450 cytochromes using fluorescent substrates

  2017cites this paper
• Microfluidic gut-on-a-chip with three-dimensional villi structure

  2017cites this paper
• Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors

  2017cites this paper
• Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.

  2017cites this paper
• Microfluidic Gut-liver chip for reproducing the first pass metabolism

  2017cites this paper
• Regulation of hepatic abcb4 and cyp3a65 gene expression and multidrug/multixenobiotic resistance (MDR/MXR) functional activity in the model teleost, Danio rerio (zebrafish).

  2017cites this paper
• Chapter 1 Introduction EG van de Kerkhof IAM de Graaf GMM Groothuis

  2017cites this paper
• Variation in Methodologies – Isolation of Intestinal Microsomes

  2016cites this paper
• Enhancing the bioavailability of BCS Class IV drugs using polymeric nanoparticles

  2016cites this paper
• Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

  2016cites this paper
• Presystemic and First‐Pass Metabolism

  2016cites this paper
• The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: Interplay between formulation and inhibition of gut wall and liver metabolism

  2016cites this paper
• Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models

  2016cites this paper
• Développement et utilisation de modèles in vitro et de données précliniques pour augmenter la prédictibilité de la perméabilité et du métabolisme intestinal chez l'humain

  2016cites this paper
• Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment

  2015cites this paper
• Dealing with the complex drug-drug interactions: towards mechanistic models.

  2015cites this paper
• Towards a fully mechanistic prediction of oral drug absorption: Investigating intestinal transporter abundance and function relationships

  2015cites this paper
• Development and applications of physiologically-based pharmacokinetic models for population data analyses

  2015cites this paper
• A Transit Compartment Model Unmasks OxyContin's Reflective Pharmacokinetics From Urine Measurements in Humans

  2014cites this paper
• Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863

  2014cites this paper
• Selected aspects of chronobiological studies in anaesthesia

  2014cites this paper
• Variability in human in vitro enzyme kinetics.

  2014cites this paper
• Mechanistic prediction of intestinal first-pass metabolism using in vitro data in preclinical species and in man

  2014influential citation
• Diclofenac toxicity in human intestine ex vivo is not related to the formation of intestinal metabolites

  2014cites this paper
• The influence of the time of day on midazolam pharmacokinetics and pharmacodynamics in rabbits

  2014cites this paper
• Application of gas chromatography-mass spectrometry in analyzing pharmacokinetics and distribution of deltamethrin in miniature pig tissues.

  2014cites this paper
• Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

  2014cites this paper
• Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs

  2014cites this paper
• PBPK models for the prediction of in vivo performance of oral dosage forms.

  2014influential citation
• Impact of selected herbal products on intestinal epithelial permeation and metabolism of indinavir

  2014cites this paper
• In Vitro–In Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds

  2014cites this paper
• Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling.

  2014cites this paper
• Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.

  2013cites this paper
• Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics.

  2013cites this paper
• A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.

  2013cites this paper
• Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.

  2013cites this paper
• Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human

  2013cites this paper
• Different Effects of Clopidogrel and Clarithromycin on the Enantioselective Pharmacokinetics of Sibutramine and its Active Metabolites in Healthy Subjects

  2013cites this paper
• Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique.

  2013cites this paper
• In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat.

  2013cites this paper
• Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.

  2013cites this paper
• Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children

  2013cites this paper
• Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam

  2013influential citation
• Presystemic metabolism of AZ'0908, a novel mPGES-1 inhibitor: an in vitro and in vivo cross-species comparison.

  2013cites this paper
• Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes

  2012influential citation
• Allele and Genotype Frequencies of CYP2B6 and CYP2C19 Polymorphisms in Egyptian Agricultural Workers

  2012cites this paper
• Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing

  2012cites this paper
• Applications Using Caco‐2 and TC7 Cells for Drug Metabolism Studies

  2012cites this paper
• Automatable microplate-based in vitro assays for screening intestinal drug transport and metabolism

  2012cites this paper
• In vitro methods to study the interplay of drug metabolism and efflux in the intestine.

  2012cites this paper
• Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog

  2012cites this paper